|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12...678910111213141516...1819» |
- | Cosentyx (secukinumab) / Novartis
Enrollment open: CLEAR: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (clinicaltrials.gov) - Mar 6, 2014
P3, N=640, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting
- ||||| alclometasone dipropionate ointment/cream / Generic mfg.
New P2 trial: Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream (clinicaltrials.gov) - Feb 27, 2014
P2, N=310, Completed, Sponsor: GlaxoSmithKline
- || Cosentyx (secukinumab) / Novartis
New P3 trial: CLEAR: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (clinicaltrials.gov) - Feb 27, 2014
P3, N=640, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Trial completion: Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis (clinicaltrials.gov) - Feb 26, 2014
P2, N=90, Completed, Sponsor: G. Pohl-Boskamp GmbH & Co. KG
Not yet recruiting --> Recruiting Recruiting --> Completed
- Orencia (abatacept) / BMS, Stelara (ustekinumab) / J&J
Trial initiation date: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Feb 23, 2014
P2, N=140, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Initiation date: Nov 2013 --> Feb 2014
- Orencia (abatacept) / BMS, Stelara (ustekinumab) / J&J
Enrollment open: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Feb 23, 2014
P2, N=140, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Nov 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- ||| siplizumab (TCD601) / ITBMed
Trial completion: Long-Term Follow-Up Study of Psoriasis Patients (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=200, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- | pimecrolimus topical / Generic mfg.
Trial completion: Efficacy of Elidel Cream on Erosive Oral Lichen Planus (clinicaltrials.gov) - Feb 22, 2014
P3, N=20, Completed, Sponsor: University Hospital Tuebingen
No longer recruiting --> Completed Recruiting --> Completed
- |||| tgAAC94 gene therapy / Armata, Amgen
Trial completion: Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=120, Completed, Sponsor: Targeted Genetics Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- || Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis (clinicaltrials.gov) - Feb 22, 2014
P3, N=30, Completed, Sponsor: Rockefeller University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial completion: An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW) (clinicaltrials.gov) - Feb 22, 2014
P4, N=18, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Recruiting --> Completed
- Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=6, Completed, Sponsor: Rockefeller University
Recruiting --> Completed No longer recruiting --> Completed
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=20, Completed, Sponsor: Rockefeller University
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Dexamethasone to Treat Oral Lichen Planus (clinicaltrials.gov) - Feb 22, 2014
P2, N=70, Completed, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
No longer recruiting --> Completed Recruiting --> Completed
- | hydroxychloroquine / Generic mfg.
Trial completion: Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus (clinicaltrials.gov) - Feb 22, 2014
P2, N=74, Completed, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: Impact of Literacy Level on Patient Education and Health Among People With Arthritis (clinicaltrials.gov) - Feb 19, 2014
P2, N=134, Completed, Sponsor: Brigham and Women's Hospital
Recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Conditioning, the Placebo Effect, and Psoriasis (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=138, Completed, Sponsor: University of Rochester
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Study of Psoriatic Arthritis (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=999, Completed, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
No longer recruiting --> Completed Recruiting --> Completed
- |||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
Enrollment open: BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab (clinicaltrials.gov) - Feb 18, 2014
P2, N=160, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Feb 15, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - Feb 12, 2014
P3, N=200, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- calcipotriol/betamethasone dipropionate / Generic mfg.
Enrollment closed: TRIANGLE: Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris (clinicaltrials.gov) - Feb 12, 2014
P4, N=200, Active, not recruiting, Sponsor: Jooheung Lee
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis (clinicaltrials.gov) - Feb 12, 2014
P3, N=95, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: DPN: Dermatosis Papulosa Nigra (clinicaltrials.gov) - Feb 11, 2014
P=N/A, N=10, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial initiation date: Initial Treatment With Golimumab in Early PsA (clinicaltrials.gov) - Feb 9, 2014
P3, N=60, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Active, not recruiting --> Completed Initiation date: Jun 2013 --> Sep 2013
- | Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment open: Initial Treatment With Golimumab in Early PsA (clinicaltrials.gov) - Feb 9, 2014
P3, N=60, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Initiation date: Jun 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- |||| Stelara (ustekinumab) / J&J
Trial completion: MARCOPOLO: A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries (clinicaltrials.gov) - Feb 4, 2014
P4, N=169, Completed, Sponsor: Johnson & Johnson Pte Ltd
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
New P2 trial: BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab (clinicaltrials.gov) - Feb 2, 2014
P2, N=160, Recruiting, Sponsor: Boehringer Ingelheim
- Enrollment closed: Blue Light for Treating Psoriasis Vulgaris (clinicaltrials.gov) - Jan 29, 2014
P=N/A, N=50, Active, not recruiting, Sponsor: Light and Health Venture
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (clinicaltrials.gov) - Jan 28, 2014
P3, N=264, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie
Trial termination, HEOR: Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=30, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Terminated; This study was prematurely terminated due to low enrollment and not for safety reasons.
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, HEOR: Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=30, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Terminated; This study was prematurely terminated due to low enrollment and not for safety reasons. N=75 --> 30
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (clinicaltrials.gov) - Jan 27, 2014
P3, N=182, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=75 --> 30 Completed --> Active, not recruiting
- ||| Enrollment open: To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=125, Recruiting, Sponsor: AbbVie
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- | Cosentyx (secukinumab) / Novartis
Biomarker, Enrollment closed: Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients (clinicaltrials.gov) - Jan 23, 2014
P2, N=36, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Stelara (ustekinumab) / J&J
Trial completion: A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS) (clinicaltrials.gov) - Jan 23, 2014
P3, N=110, Completed, Sponsor: Centocor, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept (clinicaltrials.gov) - Jan 20, 2014
P3, N=77, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed: Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept (clinicaltrials.gov) - Jan 19, 2014
P4, N=217, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ordesekimab (AMG 714) / Amgen, Provention Bio
Enrollment change: AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects (clinicaltrials.gov) - Jan 16, 2014
P2, N=22, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting N=66 --> 22
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice (clinicaltrials.gov) - Jan 16, 2014
P=N/A, N=4626, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=66 --> 22 Active, not recruiting --> Completed
- | ordesekimab (AMG 714) / Amgen, Provention Bio
Trial completion: AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects (clinicaltrials.gov) - Jan 16, 2014
P2, N=22, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| calcipotriol/betamethasone dipropionate / Generic mfg.
New P2 trial: An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects (clinicaltrials.gov) - Jan 14, 2014
P2, N=100, Not yet recruiting, Sponsor: LEO Pharma
- ||||||| Trial completion: A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304) (clinicaltrials.gov) - Jan 13, 2014
P3, N=220, Completed, Sponsor: Therapeutics, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P3 trial: AMVISION-1: Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Jan 6, 2014
P3, N=630, Recruiting, Sponsor: Amgen
- Enrollment open: Comparative Analysis of Small and Large Plaque Psoriasis (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=43, Recruiting, Sponsor: Rockefeller University
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jan 6, 2014
P3, N=425, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- trichuris suis ova (CNDO-201) / Fortress
Enrollment closed: Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Dec 29, 2013
P1, N=8, Active, not recruiting, Sponsor: Mark Lebwohl
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Impact of Literacy Level on Patient Education and Health Among People With Arthritis (clinicaltrials.gov) - Dec 22, 2013
P2, N=134, Completed, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting N=100 --> 134
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - Dec 18, 2013
P3, N=200, Recruiting, Sponsor: AbbVie
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment change: Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis (clinicaltrials.gov) - Dec 18, 2013
P=N/A, N=9, Terminated, Sponsor: Department of Veterans Affairs
N=100 --> 134 N=18 --> 9